Sofidel America will invest in a state-of-the-art Valmet tissue line to meet the growing demand of ultra-premium tissue products in the North American market.
The new Advantage ThruAir tissue line will enable Sofidel America to significantly expand its production capacity of ultra-premium products for North American consumers. Valmet’s full scope of supply includes a complete tissue production line, an automation package and flow control and Industrial Internet solutions. The collaboration between the companies spans more than three decades. Currently, Sofidel operates 20 tissue lines. The latest collaboration project, an Advantage DCT line, started up at Sofidel’s Circleville, Ohio, USA mill in September 2025.
“With this new, significant investment, we are putting down even stronger roots in the United States, improving our ability to meet customer demand and further enhancing our capacity to supply first-quality products through TAD technology. The Advantage ThruAir technology is a benchmark in the industry for efficient production of the excellent tissue quality which will support our growth in United States. The successful start-up of the new line in Circleville in September was a testament to trust and mutual respect that characterized the teamwork throughout the project. We expect the same success in the new project,” says Luigi Lazzareschi, CEO, Sofidel.
“This is a milestone for our tissue business and the largest full-scope tissue delivery for Valmet to date. Our long-lasting partnership with Sofidel is built on shared values of innovation, expertise and teamwork. The new production line will feature the latest advancements in production efficiency, capacity and environmental performance supporting their long-term goals. We are proud to be trusted with yet another project, working together for common success,” says Jon Jested-Rask, Executive Vice President, Tissue Business Area at Valmet. The order is included in Valmet’s orders received of the third quarter of 2025. The start-up of the new tissue line is scheduled for the second quarter of 2028.
